View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 10, 2022

Silence Therapeutics reports positive Phase I data for lipoprotein (a) asset

The trial analysed the safety, tolerability pharmacodynamics and pharmacokinetics of SLN360 in 32 adult subjects.

Silence Therapeutics has reported positive topline data from a Phase I trial of its SLN360 in adults with high lipoprotein(a) (Lp(a)).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An investigational small interfering ribonucleic acid (siRNA) SLN360 can potentially reduce the production of Lp(a) by acting on messenger RNA transcribed from the LPA gene.

The trial analysed the safety, tolerability, pharmacodynamics and pharmacokinetics (PK) of escalating doses of SLN360 in 32 adult subjects.

Trial subjects had plasma concentrations of Lp(a) ≥150nmol/L without any identified cardiovascular disease. 

Participants were randomised to receive either 30mg, 100mg, ≤ 300mg or ≤ 600mg single subcutaneous dose of SLN360 or placebo and were monitored for up to 150 days.

Evaluating treatment-emergent adverse events was the primary safety objective of the trial. 

Findings showed that no clinically relevant safety concerns were identified. 

Low-grade adverse events were noted at the injection site, of which more prominent were reported at the high dose. 

Furthermore, SLN360’s systemic exposures (PK) increased dose proportionally.

Percent change from baseline in Lp(a) was the key efficacy analysis of the trial. 

SLN360 showed to lower Lp(a) from 46% to nearly 98% in a dose-dependent manner while up to an 81% reduction continued at 150 days. 

To analyse the action period further, the follow-up period of the trial was expanded from 150 days to 365 days.

The company expects results from this extended period in the third quarter of this year.

Silence Therapeutics R&D head, executive vice-president and chief medical officer Giles Campion said: “These first-in-human data for SLN360, which align with our pre-clinical findings, reinforce our confidence in its potential to substantially lower Lp(a) levels with long-lasting action and address a major unmet need in cardiovascular disease. 

“More broadly, siRNA is proving to be a powerful modality for treating genetic conditions, both common and rare, by precisely engaging targets that have previously been considered ‘undruggable’.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena